Mutations in several genes cause nonautoimmune diabetes, but numerous patients still have unclear genetic defects, hampering our understanding of the development of the disease and preventing pathogenesis-oriented treatment. We used whole-genome sequencing with linkage analysis to study a consanguineous family with early-onset antibody-negative diabetes and identified a novel deletion in PCBD1 (pterin-4 α-carbinolamine dehydratase/dimerization cofactor of hepatocyte nuclear factor 1 α), a gene that was recently proposed as a likely cause of diabetes. A subsequent reevaluation of patients with mild neonatal hyperphenylalaninemia due to mutations in PCBD1 from the BIODEF database identified three additional patients who had developed HNF1A-like diabetes in puberty, indicating early β-cell failure. We found that Pcbd1 is expressed in the developing pancreas of both mouse and Xenopus embryos from early specification onward showing colocalization with insulin. Importantly, a morpholino-mediated knockdown in Xenopus revealed that pcbd1 activity is required for the proper establishment of early pancreatic fate within the endoderm. We provide the first genetic evidence that PCBD1 mutations can cause early-onset nonautoimmune diabetes with features similar to dominantly inherited HNF1A-diabetes. This condition responds to and can be treated with oral drugs instead of insulin, which is important clinical information for these patients. Finally, patients at risk can be detected through a newborn screening for phenylketonuria.

Diabetes is classified into type 1 diabetes (T1D) caused by autoimmune β-cell destruction; type 2 diabetes (T2D), caused by relative insulin deficiency in face of insulin resistance; gestational diabetes mellitus; and other specific types, including monogenic diabetes (1). T2D is a polygenic disease with over 60 susceptibility loci and numerous risk variants colocated with genes, causing monogenic diabetes (2). Monogenic diabetes is defined by neonatal, childhood, or a postpubertal age of onset, variable clinical presentation, a lack of autoimmunity, and acanthosis nigricans as well as uncommon obesity and ketoacidosis outside the neonatal period. It affects ∼1% of diabetic patients (1,3). Interestingly, monogenic cases are often accompanied by endogenous insulin production and lack of insulin resistance. Heterozygous GCK, HNF1A, and HNF4A mutations are the most common cause, although more than 20 other genes have been described (3,4). However, the disease-causing variants in numerous families remain obscure. Identifying novel genes would provide insights into pathogenesis and suggest new treatment strategies for rare monogenic diabetes as well as common polygenic T1D and T2D.

We sought to identify additional genes by combining linkage analysis with the whole-genome sequencing of a consanguineous family 1 (Fig. 1A and Table 1) with nonautoimmune diabetes and no pathogenic mutations in HNF1A, HNF1B, HNF4A, INS, ABCC8, or KCNJ11 genes. Our institutional review boards approved the studies and written consent was obtained from the participants or their guardians.

Figure 1

Mutations in PCBD1 cause early-onset diabetes. A: Pedigree of family 1 with proband III-2 having an early-onset diabetes due to homozygous mutation p.[(L16Cfs*5)];[(L16Cfs*5)]. Three of the tested relatives (I-4, II-1, II-2) have the same heterozygous mutation and diabetes. Here and in the following panels, individuals with adolescent-onset diabetes are marked in black and with mid-adulthood–onset diabetes in gray. Red borders mark individuals used in linkage analysis and red asterisks mark individuals whose whole genome was sequenced. B: Spherograms of direct-sequenced individuals of family 1 showing the homozygous mutation in the proband III-2 and heterozygous mutation in three family members with diabetes. C: Linkage analysis of family 1 showing the PCBD1 mutation (arrow) in the chromosome 10 linkage region with expected maximal LOD score of 1.3. D: Pedigree of family 2 with proband II-1 suffering with adolescent-onset diabetes and carrying a compound heterozygous mutation p.[(E97K)];[(Q98*)]. Both parents who possess one diseased allele are healthy. E: Pedigree of family 3 with both children bearing the biallelic p.[(E87*)];[(E87*)] mutation. Only II-2 has developed adolescent-onset diabetes so far. The father, a heterozygous mutation carrier, developed diabetes later in life, whereas the mother is healthy. F: Pedigree of family 4. The proband II-1, possessing a homozygous p.[(Q98*)];[(Q98*)] mutation, developed diabetes early in life. His heterozygous parents are healthy. G: Location of known disease-causing mutations in PCBD1 cDNA and protein. Mutations marked in red manifested as puberty-onset diabetes. Arrow marks the mutation first identified in our study. Blue lines show the positions of His62, His63, and His80 residues present in the active center of PCBD1 enzyme.

Figure 1

Mutations in PCBD1 cause early-onset diabetes. A: Pedigree of family 1 with proband III-2 having an early-onset diabetes due to homozygous mutation p.[(L16Cfs*5)];[(L16Cfs*5)]. Three of the tested relatives (I-4, II-1, II-2) have the same heterozygous mutation and diabetes. Here and in the following panels, individuals with adolescent-onset diabetes are marked in black and with mid-adulthood–onset diabetes in gray. Red borders mark individuals used in linkage analysis and red asterisks mark individuals whose whole genome was sequenced. B: Spherograms of direct-sequenced individuals of family 1 showing the homozygous mutation in the proband III-2 and heterozygous mutation in three family members with diabetes. C: Linkage analysis of family 1 showing the PCBD1 mutation (arrow) in the chromosome 10 linkage region with expected maximal LOD score of 1.3. D: Pedigree of family 2 with proband II-1 suffering with adolescent-onset diabetes and carrying a compound heterozygous mutation p.[(E97K)];[(Q98*)]. Both parents who possess one diseased allele are healthy. E: Pedigree of family 3 with both children bearing the biallelic p.[(E87*)];[(E87*)] mutation. Only II-2 has developed adolescent-onset diabetes so far. The father, a heterozygous mutation carrier, developed diabetes later in life, whereas the mother is healthy. F: Pedigree of family 4. The proband II-1, possessing a homozygous p.[(Q98*)];[(Q98*)] mutation, developed diabetes early in life. His heterozygous parents are healthy. G: Location of known disease-causing mutations in PCBD1 cDNA and protein. Mutations marked in red manifested as puberty-onset diabetes. Arrow marks the mutation first identified in our study. Blue lines show the positions of His62, His63, and His80 residues present in the active center of PCBD1 enzyme.

Table 1

Clinical characteristics of patients with biallelic PCBD1 mutations

Patient No.
ECRC 7, 
Family 1, III-2BIODEF§ 319, Family 2, II-1BIODEF 344, Family 3, II-2BIODEF 273, Family 3, II-1BIODEF 272, Family 4, II-1BIODEF 329, 
Family 5BIODEF 701, Family 6BIODEF 620, Family 7
Sex Female Female Female Male Male Male Female Female 
Present age, years 20 17 21 20 20 18 
Ethnicity Turkish Caucasian Ashkenazi Jewish Ashkenazi Jewish Caucasian Turkish Caucasian Caucasian 
Consanguinity Yes No No No No Yes No No 
Nucleotide aberration^ c.[(46del)]; [(46del)] c.[(289G>A)]; [(292C>T)] c.[(259G>T)]; [(259G>T)] c.[(259G>T)]; [(259G>T)] c.[(292C>T)]; [(292C>T)] c.[(79G>T;263G>A)]; [(79G>T;263G>A)] c.[(292C>T)]; [(292C>T)] c.[(292C>T)]; [(213_215del)] 
Protein alteration p.[(Leu16Cysfs*5)]; [(Leu16Cysfs*5)] p.[(Glu97Lys)]; [(Gln98*)] p.[(Glu87*)]; [(Glu87*)] p.[(Glu87*)]; [(Glu87*)] p.[(Gln98*)]; [(Gln98*)] p.[(Glu27*;Asp88Gln)]; [(Glu27*;Asp88Gln)] p.[(Gln98*)]; [(Gln98*)] p.[(Asn71del)]; [(Gln98*)] 
Variation identification Novel (CM981485); rs121913015 (CM981486) rs104894172 (CM930575) rs104894172 (CM930575) rs121913015 (CM981486) CM981482; rs115117837 (CM981484) rs121913015 (CM981486) rs121913015 (CM981486); Novel 
Diabetes Yes Yes Yes No Yes No No No 
 Onset, years 14 15 12 — 18 — — — 
 Symptoms Glucosuria, polyuria Polyuria, polydipsia Glucosuria — Polyuria, polydipsia — — — 
 IBGL, mg/dL 275 270 262 — 414 — 69 89 
 Initial BMI, (z-score) 23.4 (+2.1) 20.2 (+0.4) 21.3 (+1.4) — 20.1 (−0.4) 26.3 (+0.9) 16.5 (+0.1) 17.3 (+1.1) 
 Initial HbA1c, % (mmol/mol) 7.8 (62) 6.5 (48) <6.1 (43) — 14.6 (136) 4.9 (30) 4.3 (23) 4.9 (30) 
 β-Cell autoantibodies Negative Negative Negative N.D. Negative N.D. N.D. N.D. 
 Pancreas morphology Normal N.D. N.D. N.D. Normal Normal N.D. N.D. 
 Treatment Insulin, meglitinide Insulin, sulfonylurea Insulin, sulfonylurea, lifestyle — Insulin, sulfonylurea — — — 
 Family history Father, mother, and maternal grandmother T2D Both parents healthy Mother healthy, father T2D, obesity Mother healthy, father T2D, obesity Both parents healthy, maternal grandparents T2D Both parents healthy Both parents healthy, maternal grandfather T2D Both parents healthy 
HPA status No Yes No Yes Yes Yes Yes Yes 
Reference Unpublished 10, 12  11  11  11, 12  10, 12  Unpublished Unpublished 
Patient No.
ECRC 7, 
Family 1, III-2BIODEF§ 319, Family 2, II-1BIODEF 344, Family 3, II-2BIODEF 273, Family 3, II-1BIODEF 272, Family 4, II-1BIODEF 329, 
Family 5BIODEF 701, Family 6BIODEF 620, Family 7
Sex Female Female Female Male Male Male Female Female 
Present age, years 20 17 21 20 20 18 
Ethnicity Turkish Caucasian Ashkenazi Jewish Ashkenazi Jewish Caucasian Turkish Caucasian Caucasian 
Consanguinity Yes No No No No Yes No No 
Nucleotide aberration^ c.[(46del)]; [(46del)] c.[(289G>A)]; [(292C>T)] c.[(259G>T)]; [(259G>T)] c.[(259G>T)]; [(259G>T)] c.[(292C>T)]; [(292C>T)] c.[(79G>T;263G>A)]; [(79G>T;263G>A)] c.[(292C>T)]; [(292C>T)] c.[(292C>T)]; [(213_215del)] 
Protein alteration p.[(Leu16Cysfs*5)]; [(Leu16Cysfs*5)] p.[(Glu97Lys)]; [(Gln98*)] p.[(Glu87*)]; [(Glu87*)] p.[(Glu87*)]; [(Glu87*)] p.[(Gln98*)]; [(Gln98*)] p.[(Glu27*;Asp88Gln)]; [(Glu27*;Asp88Gln)] p.[(Gln98*)]; [(Gln98*)] p.[(Asn71del)]; [(Gln98*)] 
Variation identification Novel (CM981485); rs121913015 (CM981486) rs104894172 (CM930575) rs104894172 (CM930575) rs121913015 (CM981486) CM981482; rs115117837 (CM981484) rs121913015 (CM981486) rs121913015 (CM981486); Novel 
Diabetes Yes Yes Yes No Yes No No No 
 Onset, years 14 15 12 — 18 — — — 
 Symptoms Glucosuria, polyuria Polyuria, polydipsia Glucosuria — Polyuria, polydipsia — — — 
 IBGL, mg/dL 275 270 262 — 414 — 69 89 
 Initial BMI, (z-score) 23.4 (+2.1) 20.2 (+0.4) 21.3 (+1.4) — 20.1 (−0.4) 26.3 (+0.9) 16.5 (+0.1) 17.3 (+1.1) 
 Initial HbA1c, % (mmol/mol) 7.8 (62) 6.5 (48) <6.1 (43) — 14.6 (136) 4.9 (30) 4.3 (23) 4.9 (30) 
 β-Cell autoantibodies Negative Negative Negative N.D. Negative N.D. N.D. N.D. 
 Pancreas morphology Normal N.D. N.D. N.D. Normal Normal N.D. N.D. 
 Treatment Insulin, meglitinide Insulin, sulfonylurea Insulin, sulfonylurea, lifestyle — Insulin, sulfonylurea — — — 
 Family history Father, mother, and maternal grandmother T2D Both parents healthy Mother healthy, father T2D, obesity Mother healthy, father T2D, obesity Both parents healthy, maternal grandparents T2D Both parents healthy Both parents healthy, maternal grandfather T2D Both parents healthy 
HPA status No Yes No Yes Yes Yes Yes Yes 
Reference Unpublished 10, 12  11  11  11, 12  10, 12  Unpublished Unpublished 

ECRC, Experimental and Clinical Research Center; HPA, hyperphenylalaninemia during neonatal period; IBGL, initial blood glucose levels; N.D., not done.

^Positions refer to Consensus CDS database accession number 31217.1. RefSeq number for human PCBD1 mRNA is NM_000281.2.

†dbSNP and/or Human Gene Mutation Database (in brackets) database accession numbers.

‡Determined by abdominal ultrasound.

§BIODEF database.

To pinpoint suggestive linkage regions, we performed a haplotype mapping and parametric linkage analysis of seven members of family 1 (Fig. 1A, red borders) using HumanCytoSNP-12 v2.1 BeadChip (Illumina) and Merlin software, assuming recessive inheritance, complete penetrance, and a disease allele frequency of 0.001. We obtained 24 genomic regions with positive logarithm of odds (LOD) scores, including 13 regions on 10 chromosomes with maximal LOD score of 1.3 (Supplementary Fig. 1). We next performed a whole-genome sequencing of five individuals from family 1 (Fig. 1A, asterisks) on the Complete Genomics platform (Mountain View, CA). The Complete Genomics pipeline was used for read mapping and allele calling. On average, both alleles were called for ∼96% genomic and ∼98% exonic positions, whereas ∼97% and ∼99% of the called ones were covered by at least 10 reads, respectively (Supplementary Table 1). We found ∼4 million small variations (small indels and single nucleotide polymorphisms [SNPs]) per individual genome including more than 23,000 variants in each exome.

To distinguish relevant SNPs and small indels from other variations, we used Complete Genomics Analysis Tools, ANNOVAR, and custom scripts. We first removed intergenic variants and anticipated recessive inheritance (Supplementary Fig. 2). Therefore, homozygous variants were required to be present in index case III-2 and heterozygous in II-1, II-2, and I-4, but not in I-3, who is not related to I-4. As monogenic diabetes is uncommon, we predicted the disease-causing variant to be rare and likely not yet identified. Thus, we removed all the variants present in dbSNP 137; 1000 Genomes Project; National Heart, Lung, and Blood InstituteExome Sequencing Project; 69 sequenced individuals from Complete Genomics; and our in-house database of nondiabetic individuals. We focused on nonsynonymous variants, splice site mutations, and small indels within protein-coding regions. We further selected conserved alterations, as defined by phastCons, and variants predicted to be deleterious by at least two tools: SIFT, PolyPhen-2, or MutationTaster. This reasoning left six genes (Supplementary Table 1), from which we selected PCBD1, encoding pterin-4 α-carbinolamine dehydratase also known as dimerization cofactor of hepatocyte nuclear factor 1 α (DCoH) (5), for further analysis. Our decision was based on the strong expression of PCBD1 in pancreatic islets (T1DBase and ref. 6), mouse pancreatic progenitors (7), and its interaction with HNF1A and HNF1B transcription factors, essential for proper pancreatic β-cell function (5,8,9). Moreover, PCBD1 lay within the suggestive linkage region (Fig. 1C) and was the only gene containing a frameshift deletion. Subsequently, we validated the deletion in all diabetic members of family 1 by Sanger sequencing (Fig. 1B), using exon-intron spanning primers (Supplementary Table 1).

PCBD1 is a bifunctional protein that acts as an enzyme in the regeneration of cofactor tetrahydrobiopterin (BH4) (10), crucial for the function of aromatic amino acid hydroxylases, and as a dimerization cofactor of transcription factors HNF1A and HNF1B (5), which are important in liver and pancreas development and function. The enzymatic function of PCBD1 is defective in newborns with mild transient hyperphenylalaninemia (HPA) and high urinary levels of primapterin caused by recessive mutations (11,12). Recently, a PCBD1 defect was suggested to cause hypomagnesemia and diabetes (13). The novel homozygous deletion c.46del in family 1 results in a premature stop codon p.[(Lys16Cys*5)];[(Lys16Cys*5)] that abolishes the transcription factor–binding and enzymatic functions of PCBD1 (Fig. 1G).

As III-2 developed diabetes in puberty, we reevaluated patients with neonatal HPA caused by PCBD1 who appeared in the BIODEF database (14). Three out of seven children from six families, exhibiting three different biallelic PCBD1 defects of p.[(Glu87*)];[(Glu87*)], p.[(Glu97Lys)];[(Gln98*)], and p.[(Gln98*)];[(Gln98*)], had already developed antibody-negative diabetes with normal pancreatic morphology (Fig. 1D–F and Table 1). Taken together, our analyses of seven independent families provide strong genetic evidence that mutations in PCBD1 cause puberty-onset diabetes.

We tested the in vitro effects of a transient Pcbd1 knockdown in glucose-sensitive mouse insulinoma cells using small interfering RNA and found no obvious defects in insulin production or glucose-stimulated insulin secretion after an 80% inactivation of Pcbd1 (data not shown). Endocrine pancreas dysfunction not only may arise from β-cell inability to produce and/or secrete insulin but also from impaired β-cell development, proliferation, and adaptation during fetal, neonatal, and pubertal age. To address whether Pcbd1 controls early pancreas development and/or pancreatic β-cell fate specification, we first examined its expression pattern in the developing pancreas of both mouse and Xenopus embryos (Supplementary Data). In the mouse embryo, Pcbd1 transcript has been reported in the foregut endoderm, which contains liver and pancreas progenitors at embryonic stage (E) 8.5, and in E10.5 liver and ventral and dorsal pancreatic buds (7). We found an abundant expression of Pcbd1 in the embryonic pancreas at E12.5 and E14.5 (Fig. 2A–D). Interestingly, Pcbd1 accumulated in endocrine progenitors that had started to delaminate from E-cadherin–positive pancreatic epithelium and expressed insulin (Fig. 2A’ and C’). At E14.5, Pcbd1 expression was maintained in endocrine progenitors and was visible throughout the pancreatic epithelium (Fig. 2D). To analyze if this pcbd1 expression pattern was conserved in Xenopus endoderm, we performed reverse transcription-quantitative PCR (RT-qPCR) on microdissected endoderm cells. Fate map experiments in Xenopus have previously shown that pancreatic progenitors arise from anterior endoderm (AE), whereas posterior endoderm (PE) forms mainly intestine (15). We found that pcbd1 along with the pancreatic genes pdx1 and ptf1a marks future pancreatic endoderm, being expressed at higher levels in AE than in PE from the gastrula stage onward (Fig. 2E and data not shown). The pcbd1 binding partners, hnf1a and hnf1b, displayed similar expression profiles, whereas the close homolog pcbd2 was almost absent from AE cells (Fig. 2E). Furthermore, an in situ hybridization in Xenopus embryos showed pcbd1 expression in pancreatic rudiments, overlapping with the expression pattern of insulin (Fig. 2F–I). Overall, these results indicate that Pcbd1 is expressed in the developing pancreas of both mouse and Xenopus embryos, suggesting a potential evolutionarily conserved function.

Figure 2

Pcbd1 in mouse and Xenopus embryonic pancreas. AD: Immunofluorescence analysis of Pcbd1, Pdx1, Insulin (Ins), and E-cadherin (E-cad) on E12.5 (A, C) and E14.5 (B, D) in 10-μm cryosections of mouse pancreas epithelium. Dashed boxes indicate delaminating endocrine cells, which displayed strong nuclear and cytoplasmic Pcbd1 expression and coexpressed Ins (C’ and D) or Pdx1 (A’ and B). Bar, 50 μm. E: PE and AE explants were dissected at early gastrula stage, cultured until indicated stages, and assayed for expression of the indicated genes by RT-qPCR analysis. At all stages analyzed, pcbd1 expression mirrored that of AE markers, such as foxa2, hnf1a, and hnf1b, and of pancreatic transcription factors, such as pdx1 and ptf1a. Data were normalized to that of ornithine decarboxylase 1 (ODC) and represented as fold changes compared with PE sample (set to 1). Error bars represent ± SD. P values were calculated using Student t test: ns = P > 0.05, *P < 0.05, **P < 0.01, ***P < 0.001. FI: Whole-mount in situ hybridization for pcbd1 in Xenopus embryos and dissected gut (performed as described previously [25]). Pcbd1 transcript was detected in dorsal pancreas (G, I), overlapping with insulin-expression domain (F, H). dp, dorsal pancreas; lv, liver; pa, pancreas, pn, pronephros. Bar, 1 mm.

Figure 2

Pcbd1 in mouse and Xenopus embryonic pancreas. AD: Immunofluorescence analysis of Pcbd1, Pdx1, Insulin (Ins), and E-cadherin (E-cad) on E12.5 (A, C) and E14.5 (B, D) in 10-μm cryosections of mouse pancreas epithelium. Dashed boxes indicate delaminating endocrine cells, which displayed strong nuclear and cytoplasmic Pcbd1 expression and coexpressed Ins (C’ and D) or Pdx1 (A’ and B). Bar, 50 μm. E: PE and AE explants were dissected at early gastrula stage, cultured until indicated stages, and assayed for expression of the indicated genes by RT-qPCR analysis. At all stages analyzed, pcbd1 expression mirrored that of AE markers, such as foxa2, hnf1a, and hnf1b, and of pancreatic transcription factors, such as pdx1 and ptf1a. Data were normalized to that of ornithine decarboxylase 1 (ODC) and represented as fold changes compared with PE sample (set to 1). Error bars represent ± SD. P values were calculated using Student t test: ns = P > 0.05, *P < 0.05, **P < 0.01, ***P < 0.001. FI: Whole-mount in situ hybridization for pcbd1 in Xenopus embryos and dissected gut (performed as described previously [25]). Pcbd1 transcript was detected in dorsal pancreas (G, I), overlapping with insulin-expression domain (F, H). dp, dorsal pancreas; lv, liver; pa, pancreas, pn, pronephros. Bar, 1 mm.

Pcbd1 knockout mouse showed mild glucose intolerance (16), although no pancreas-specific function had yet been assigned to Pcbd1. To determine if Pcbd1 influences early pancreas fate specification, we undertook a loss-of-function approach in Xenopus. A specific morpholino oligonucleotide (pcbd1-MO) was designed to block pcbd1 pre-mRNA splicing. The injection of pcbd1-MO into AE cells of the eight-cell stage Xenopus embryos resulted in a dose-dependent downregulation of pcbd1 mRNA (Fig. 3A and data not shown), accompanied by a significant reduction in the expression of pancreatic progenitor genes pdx1, ptf1a, sox9, and insulin (Fig. 3A). Moreover, hnf1a and hnf1b and the hnf1 target gene fibrinogen were downregulated upon pcbd1-MO injection, whereas pcbd2 mRNA levels remained unchanged (data not shown). In situ hybridization of pcbd1-MO injected Xenopus embryos corroborated these observations, showing a strong reduction or complete loss of ptf1a expression in both dorsal and ventral pancreatic buds, but not in the eye and hindbrain (Fig. 3B–D ). Taken together, these results indicate that pcbd1 activity within the endoderm is required for the proper establishment of the pancreatic region in vertebrates.

Figure 3

Pcbd1-MO knockdown in Xenopus AE explants. A: RT-qPCR analysis of pcbd1-MO-injected AE explants. Pcbd1-MO (10 ng) (Gene Tools, Philomath, OR) was injected into two vegetal dorsal blastomeres of eight-cell stage Xenopus embryos, and AE explants were dissected at gastrula stage and assayed at tadpole stage for the indicated pancreatic and hepatic genes by RT-qPCR assay. Data were normalized to that of ornithine decarboxylase 1 (ODC) and represented as fold changes compared with AE uninjected control sample (set to 1). fgn, fibrinogen, ins, insulin. Error bars represent ± SD. P values were calculated using Student t test: ns = P > 0.05; *P < 0.05; **P < 0.01; ***P < 0.001. BD: Whole-mount in situ hybridization analysis of ptf1a in control and pcbd1-MO-injected Xenopus embryos. B’, C’, and D’: Vibratome transverse sections through the ventral pancreatic (vp) rudiment stained for ptf1a. B’’, C’’, and D’’: Vibratome transverse sections through the dorsal pancreatic (dp) rudiment stained for ptf1a. Dashed lines indicate the cross-sectional planes. Bar, 1 mm.

Figure 3

Pcbd1-MO knockdown in Xenopus AE explants. A: RT-qPCR analysis of pcbd1-MO-injected AE explants. Pcbd1-MO (10 ng) (Gene Tools, Philomath, OR) was injected into two vegetal dorsal blastomeres of eight-cell stage Xenopus embryos, and AE explants were dissected at gastrula stage and assayed at tadpole stage for the indicated pancreatic and hepatic genes by RT-qPCR assay. Data were normalized to that of ornithine decarboxylase 1 (ODC) and represented as fold changes compared with AE uninjected control sample (set to 1). fgn, fibrinogen, ins, insulin. Error bars represent ± SD. P values were calculated using Student t test: ns = P > 0.05; *P < 0.05; **P < 0.01; ***P < 0.001. BD: Whole-mount in situ hybridization analysis of ptf1a in control and pcbd1-MO-injected Xenopus embryos. B’, C’, and D’: Vibratome transverse sections through the ventral pancreatic (vp) rudiment stained for ptf1a. B’’, C’’, and D’’: Vibratome transverse sections through the dorsal pancreatic (dp) rudiment stained for ptf1a. Dashed lines indicate the cross-sectional planes. Bar, 1 mm.

We examined eight patients with inherited biallelic PCBD1 mutations from seven families: one case by whole-genome sequencing combined with linkage analysis, which identified a novel deletion in the PCBD1 gene and seven cases by recalling the patients from the BIODEF database (14). Interestingly, two diabetic patients (family 1, III-2 and family 3, II-2) had normal phenylalanine levels, suggesting that the enzymatic function of PCBD1 had been compensated for by PCBD2, as has been proposed for mouse (16).

Insulin was the first option of treatment of PCBD1-diabetes, subsequently replaced by sulfonylureas or glinides. This brisk response to oral drugs resembles the patients with HNF1A-diabetes (17). PCBD1-diabetes manifests earliest in puberty as no younger cases that were investigated were diabetic (Table 1). Remarkably, mid-adulthood–onset T2D developed in four out of seven families (families 1, 3, 4, and 6; Table 1 and Supplementary Table 1). We confirmed heterozygous PCBD1 defects in affected individuals of families 1 and 3. Therefore, it is likely that monoallelic variants in PCBD1 increase the risk of T2D, as has been shown for other monogenic diabetes genes (2). Moreover, it is suggestive that PCBD1 mutations increase T2D susceptibility specifically when combined with other risk factors such as excess weight and age. This is implied by the fact that only overweight/obese heterozygotes developed T2D, whereas none of those with a normal BMI did (Supplementary Table 1). Furthermore, the two overweight/obese parents who did not develop diabetes were 32 and 34 years old and thus had not yet reached the age of the onset of diabetes in the other heterozygotes.

We investigated two major mechanisms of diabetes: the production and secretion of insulin in insulinoma cells and the early regulation of pancreatic and β-cell specification in vertebrates. As PCBD1 has been described to enhance HNF1A activity on some promoters (5), we examined whether a transient inactivation of PCBD1 decreases insulin production and secretion in vitro, but failed to see any relevant effect (data not shown). Previous studies have shown that Pcbd1 is abundantly expressed throughout embryonic development in both Xenopus and mammalian embryos (18,19). Interestingly, we found that PCBD1 is expressed in mouse pancreatic progenitors (7) and delaminating endocrine cells from very early stages onward (Fig. 2A–D). This spatiotemporal expression of pcbd1 is also conserved in Xenopus embryos (Fig. 2G and I), suggesting conserved regulatory functions. In line with this, Xenopus pcbd1 morphants exhibited a reduced expression of endodermal and pancreatic transcription factors, indicating defects in early pancreas specification. Notably, both dorsal and ventral pancreatic rudiments fail to be established in pcbd1-depleted embryos, as judged by the absence of ptf1a expression (Fig. 3B–D). Altogether, these findings suggest an early role of pcbd1 in establishing the pancreatic progenitor pool during embryogenesis, which might lead to a reduced pancreatic β-cell mass in the adult. The human PCBD1-diabetes phenotype with developing insulin deficiency in the face of somatic growth and weight gain is in line with the notion that an intrinsic program established early in development is critical in determining the final size of the pancreas and is not subject to growth compensation (20).

Transcription factor HNF1B regulates early pancreatic development in mouse and human and is stabilized by PCBD1 (5,21). A lack of PCBD1 might impair the HNF1B-mediated establishment of pancreatic cell fate during embryogenesis. In Xenopus embryos, this hypothesis is supported by a reduced expression of hnf1b and its direct target genes, such as fibrinogen, upon pcbd1-MO injection. However, a Pcbd1 knockout mouse shows a relatively mild phenotype compared with Xenopus pcbd1 morphant or human HNF1A and HNF1B loss-of-function phenotypes (8,9). These differences might be due to a partial functional redundancy between Pcbd1 and the close homolog Pcbd2 in the mouse (16), which does not seem sufficient to prevent diabetes. In line with this, pcbd2 is expressed at low levels in the endoderm and is almost undetectable in the pancreatic territory of Xenopus embryos (Fig. 2E). Further experiments are required to dissect the mechanisms underlying the Pcbd1 loss-of-function phenotype and the role of Pcbd2 in its development.

Recent observations have suggested that a gradual loss of transcription factors Pdx1, Nkx6.1, and MafA, crucial for early pancreas development, leads to a destabilized adult β-cell state and an exhaustion of function, possibly contributing to the pathogenesis of T2D (22). The HNF1 family of transcription factors also controls both aspects. HNF1B is required to set up the early pancreatic transcriptional program (21), and HNF1A maintains a proper transcriptional network in mature β-cells (23). Thus, their binding partner PCBD1 might have different effects on the pancreas at different time points. Finally, PCBD1 mutations probably cause HPA and diabetes by affecting not one particular pathway but several genetic, metabolic, and signaling programs in different tissues, as shown for HNF1A gene (24). Future studies will aim to fully understand how PCBD1 regulates β-cell functions and the mechanisms leading to diabetes.

In summary, we provide the first genetic evidence that PCBD1 mutations can cause early-onset monogenic diabetes. We recommend a monitoring of neonatal HPA patients and their relatives with PCBD1 mutations in puberty and later in life for an occurrence of diabetes. We suggest screening HNF1A-like diabetes cases without mutations in HNF1A and HNF4A genes for recessive alterations in PCBD1, as they can be treated with oral antidiabetes drugs. Larger numbers of patients with PCBD1-diabetes will be needed to determine how commonly insulin can be replaced with sulfonylureas, as larger studies of individuals with HNF1A, KCNJ11, and ABCC8 defects show that this treatment is successful in most but not all the cases.

Acknowledgments. The authors thank the patients and their families. The authors also thank Nadine Wittstruck, Sabine Schmidt, and Mathias Gerhard (Cardiovascular and Metabolic Diseases, Max-Delbrück Center for Molecular Medicine, Berlin, Germany) for superb technical support; Dr. Patrick Ferreira (Division of Medical Genetics, Alberta Children’s Hospital, Calgary, Canada); Dr. Roger Germann (Children’s Hospital, Klinikum Karlsruhe, Karlsruhe, Germany); and Dr. Johannis B.C. de Klerk (Department of Pediatrics, Sophia Children’s Hospital, Erasmus Medical Center, Rotterdam, the Netherlands) for supporting the BIODEF recall and providing additional family information; and Friedrich C. Luft (Experimental and Clinical Research Center, Berlin, Germany) and Russel Hodge (Max-Delbrück Center for Molecular Medicine) for reviewing the manuscript.

Funding. The Experimental and Clinical Research Center supports K.R. The Deutsche Forschungsgemeinschaft supported M.G. (DFG: GO 1990/1-1). F.M.S. is supported by the Helmholtz Association (VH-NG-425), ERC-2009-St. Grant HEPATOPANCREATIC (243045), and FP7 IRG-ENDOPANC (239534). This work was funded (in part) by the Helmholtz Alliance ICEMED—Imaging and Curing Environmental Metabolic Diseases, through the Initiative and Networking Fund of the Helmholtz Association.

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

Author Contributions. D.S. designed, planned, and carried out experiments; analyzed the data; and wrote the manuscript. J.K. planned and carried out mouse and Xenopus experiments and analyzed the data. M.G. planned experiments, discussed the data, and reviewed the manuscript. F.R. performed linkage analysis and discussed the data. S.J. performed mouse cell culture experiments. P.A., K.B., C.E., P.K., and G.F.H. provided clinical data and contributed to the discussion. N.B. planned and carried out the recall of patients and their families from the BIODEF database, provided clinical data, and reviewed and edited the manuscript. F.M.S. designed mouse and Xenopus experiments, discussed the data, and reviewed and edited the manuscript. N.H. designed the study, discussed the data, and reviewed and edited the manuscript. K.R. designed the study, followed up the patients, performed clinical examinations, discussed the data, and reviewed and edited the manuscript. K.R. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

1.
American Diabetes Association
.
Diagnosis and classification of diabetes mellitus
.
Diabetes Care
2013
;
36
(
Suppl. 1
):
S67
S74
[PubMed]
2.
Morris
AP
,
Voight
BF
,
Teslovich
TM
, et al
Wellcome Trust Case Control Consortium
Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC) Investigators
Genetic Investigation of ANthropometric Traits (GIANT) Consortium
.
Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes
.
Nat Genet
2012
;
44
:
981
990
[PubMed]
3.
Ashcroft
FM
,
Rorsman
P
.
Diabetes mellitus and the β cell: the last ten years
.
Cell
2012
;
148
:
1160
1171
[PubMed]
4.
Ellard
S
,
Lango Allen
H
,
De Franco
E
, et al
.
Improved genetic testing for monogenic diabetes using targeted next-generation sequencing
.
Diabetologia
2013
;
56
:
1958
1963
[PubMed]
5.
Mendel
DB
,
Khavari
PA
,
Conley
PB
, et al
.
Characterization of a cofactor that regulates dimerization of a mammalian homeodomain protein
.
Science
1991
;
254
:
1762
1767
[PubMed]
6.
Eizirik
DL
,
Sammeth
M
,
Bouckenooghe
T
, et al
.
The human pancreatic islet transcriptome: expression of candidate genes for type 1 diabetes and the impact of pro-inflammatory cytokines
.
PLoS Genet
2012
;
8
:
e1002552
[PubMed]
7.
Rodríguez-Seguel
E
,
Mah
N
,
Naumann
H
, et al
.
Mutually exclusive signaling signatures define the hepatic and pancreatic progenitor cell lineage divergence
.
Genes Dev
2013
;
27
:
1932
1946
[PubMed]
8.
Lindner
TH
,
Njolstad
PR
,
Horikawa
Y
,
Bostad
L
,
Bell
GI
,
Sovik
O
.
A novel syndrome of diabetes mellitus, renal dysfunction and genital malformation associated with a partial deletion of the pseudo-POU domain of hepatocyte nuclear factor-1beta
.
Hum Mol Genet
1999
;
8
:
2001
2008
[PubMed]
9.
Yamagata
K
,
Oda
N
,
Kaisaki
PJ
, et al
.
Mutations in the hepatocyte nuclear factor-1alpha gene in maturity-onset diabetes of the young (MODY3)
.
Nature
1996
;
384
:
455
458
[PubMed]
10.
Citron
BA
,
Davis
MD
,
Milstien
S
, et al
.
Identity of 4a-carbinolamine dehydratase, a component of the phenylalanine hydroxylation system, and DCoH, a transregulator of homeodomain proteins
.
Proc Natl Acad Sci U S A
1992
;
89
:
11891
11894
[PubMed]
11.
Thöny
B
,
Neuheiser
F
,
Kierat
L
, et al
.
Hyperphenylalaninemia with high levels of 7-biopterin is associated with mutations in the PCBD gene encoding the bifunctional protein pterin-4a-carbinolamine dehydratase and transcriptional coactivator (DCoH)
.
Am J Hum Genet
1998
;
62
:
1302
1311
[PubMed]
12.
Thöny
B
,
Neuheiser
F
,
Kierat
L
, et al
.
Mutations in the pterin-4alpha-carbinolamine dehydratase (PCBD) gene cause a benign form of hyperphenylalaninemia
.
Hum Genet
1998
;
103
:
162
167
[PubMed]
13.
Ferre
S
,
de Baaij
JH
,
Ferreira
P
, et al
.
Mutations in PCBD1 cause hypomagnesemia and renal magnesium wasting
.
J Am Soc Nephrol
2014;25:574–586
[PubMed]
14.
Opladen
T
,
Hoffmann
GF
,
Blau
N
.
An international survey of patients with tetrahydrobiopterin deficiencies presenting with hyperphenylalaninaemia
.
J Inherit Metab Dis
2012
;
35
:
963
973
[PubMed]
15.
Chalmers
AD
,
Slack
JM
.
The Xenopus tadpole gut: fate maps and morphogenetic movements
.
Development
2000
;
127
:
381
392
[PubMed]
16.
Bayle
JH
,
Randazzo
F
,
Johnen
G
, et al
.
Hyperphenylalaninemia and impaired glucose tolerance in mice lacking the bifunctional DCoH gene
.
J Biol Chem
2002
;
277
:
28884
28891
[PubMed]
17.
Awa
WL
,
Thon
A
,
Raile
K
, et al
DPV-Wiss. Study Group
.
Genetic and clinical characteristics of patients with HNF1A gene variations from the German-Austrian DPV database
.
Eur J Endocrinol
2011
;
164
:
513
520
[PubMed]
18.
Strandmann
EP
,
Senkel
S
,
Ryffel
GU
.
The bifunctional protein DCoH/PCD, a transcription factor with a cytoplasmic enzymatic activity, is a maternal factor in the rat egg and expressed tissue specifically during embryogenesis
.
Int J Dev Biol
1998
;
42
:
53
59
[PubMed]
19.
Pogge yon Strandmann
E
,
Ryffel
GU
.
Developmental expression of the maternal protein XDCoH, the dimerization cofactor of the homeoprotein LFB1 (HNF1)
.
Development
1995
;
121
:
1217
1226
[PubMed]
20.
Stanger
BZ
,
Tanaka
AJ
,
Melton
DA
.
Organ size is limited by the number of embryonic progenitor cells in the pancreas but not the liver
.
Nature
2007
;
445
:
886
891
[PubMed]
21.
Barbacci
E
,
Reber
M
,
Ott
MO
,
Breillat
C
,
Huetz
F
,
Cereghini
S
.
Variant hepatocyte nuclear factor 1 is required for visceral endoderm specification
.
Development
1999
;
126
:
4795
4805
[PubMed]
22.
Guo
S
,
Dai
C
,
Guo
M
, et al
.
Inactivation of specific β cell transcription factors in type 2 diabetes
.
J Clin Invest
2013;123:3305–3316
[PubMed]
23.
Shih
DQ
,
Stoffel
M
.
Dissecting the transcriptional network of pancreatic islets during development and differentiation
.
Proc Natl Acad Sci U S A
2001
;
98
:
14189
14191
[PubMed]
24.
Servitja
JM
,
Pignatelli
M
,
Maestro
MA
, et al
.
Hnf1alpha (MODY3) controls tissue-specific transcriptional programs and exerts opposed effects on cell growth in pancreatic islets and liver
.
Mol Cell Biol
2009
;
29
:
2945
2959
[PubMed]
25.
Spagnoli
FM
,
Brivanlou
AH
.
The Gata5 target, TGIF2, defines the pancreatic region by modulating BMP signals within the endoderm
.
Development
2008
;
135
:
451
461
[PubMed]

Supplementary data